Retatrutide 10mg

Retatrutide (LY3437943) is a revolutionary, first-in-class triple hormone receptor agonist developed for the treatment of obesity, metabolic syndrome, and type 2 diabetes. Unlike previous generations of weight-loss peptides that target one or two receptors (like Semaglutide or Tirzepatide), Retatrutide simultaneously activates three critical metabolic pathways: GLP-1, GIP, and Glucagon receptors.
This synergistic “triple-G” mechanism produces unprecedented results in clinical trials, demonstrating up to 24.2% body weight reduction at 48 weeks in Phase 2 trials, and up to 28.7% at 68 weeks in Phase 3 trials . By adding glucagon receptor agonism to the established GLP-1/GIP framework, Retatrutide not only suppresses appetite and improves insulin sensitivity but also directly increases basal metabolic rate and energy expenditure.

Mechanism of Action: The “Triple-G” Synergy
Retatrutide’s unique efficacy stems from its simultaneous action on three distinct receptors:
1. GLP-1 (Glucagon-Like Peptide-1): Slows gastric emptying, significantly reduces appetite, and enhances glucose-dependent insulin secretion.
2. GIP (Glucose-Dependent Insulinotropic Polypeptide): Works synergistically with GLP-1 to improve insulin sensitivity, reduce fat accumulation, and mitigate the nausea often associated with GLP-1 activation alone.
3. Glucagon Receptor (GCGR): This is the game-changer. Glucagon activation directly stimulates lipolysis (fat breakdown) in the liver and adipose tissue, and increases resting energy expenditure. This prevents the metabolic slowdown typically seen during severe caloric restriction.

Key Benefits
• Unprecedented Weight Loss: Clinical data shows average weight reductions exceeding 24% in under a year, surpassing the efficacy of dual agonists like Tirzepatide .
• Increased Energy Expenditure: Unlike other weight-loss peptides that only reduce caloric intake, the glucagon component in Retatrutide actively increases the calories your body burns at rest.
• Hepatic Fat Reduction: Retatrutide has shown remarkable efficacy in resolving non-alcoholic fatty liver disease (NAFLD), with many trial participants achieving complete resolution of excess liver fat.
• Improved Lipid Profile: Significant reductions in LDL cholesterol and triglycerides, alongside improvements in cardiovascular risk markers.
• Metabolic Flexibility: Enhances the body’s ability to switch between burning carbohydrates and fats for fuel.

Recommended Dosing Protocol (Titration Schedule)
Retatrutide must be introduced gradually to allow the body to adapt to the triple-receptor activation and to minimize gastrointestinal side effects. The standard clinical trial titration protocol involves a once-weekly subcutaneous injection, escalating every 4 weeks.

Note: Many researchers find that lower maintenance doses (4mg or 6mg) provide sufficient efficacy without the need to escalate to the maximum 12mg dose.

• Metabolic Optimization Stack: Retatrutide + MOTS-c (to further enhance mitochondrial function and exercise capacity).